Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2003;327:1405 (13 December), doi:10.1136/bmj.327.7428.1405
| The first 150 words of the full text of this article appear below. |
EDITORNo consensus currently exists on treatment of the severe acute respiratory syndrome (SARS). Wong et al reported that all patients with SARS received broad spectrum antibiotics and a combination of ribavirin and prednisolone.1 Intravenous methylprednisolone at high dosage was used in patients with respiratory distress or progressive consolidations in a chest radiograph.
However, the treatment of SARS with ribavarin and corticosteroids remains controversial.2 Corticosteroids are administered to suppress a possible cytokine storm, which may worsen the lung injury caused by the infectious agent.2 But using corticosteroids with possibly ineffective antiviral agents in patients with virus induced pneumonitis can be hazardous.2
If corticosteroids are administered doctors must always be aware of complications such as superinfections with Aspergillus,3 a known complication in any patient receiving corticosteroids.4 Patients with SARS receiving corticosteroids should therefore be monitored for aspergillosis.
Since Aspergillus usually grows slowly on culture (taking up to six days) and
Ya Ping Wu, researcher
Department of Haematology, University Medical Centre Utrecht, 3584CX Utrecht, Netherlands ywu@azu.nl
Ran Wei, professor
Basic Medical Science Institute, Taishan Medical College, Taian, Shandong, China 271000
Jan Verhoef, professor
Eijkman-Winkler Centre for Medical Microbiology, Infectious Diseases and Inflammation, University Medical Centre Utrecht
Read all Rapid Responses